Who is affected by this change?

This affects Independence Blue Cross Dermatology, Oncology providers on Commercial plans.

When does this change take effect?

This change is effective Jan 1, 2026.

Back to dashboard

CommercialCoverageMedium impact

07.07.03o, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])

Independence Blue Cross·Dermatology, Oncology·Pharmacy

Effective date

Jan 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX has updated their commercial policy for Photodynamic Therapy (PDT) using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl) effective January 1, 2026. This policy change affects coverage and billing procedures for PDT treatments under commercial insurance plans.

Action Required

Action needed

Before January 1, 2026: Billing team must review and implement updated IBX commercial policy requirements for Photodynamic Therapy using Levulan® Kerastick® or Ameluz®. Access the full policy details at the provided URL to understand specific coverage criteria and documentation requirements. Update billing procedures and staff training accordingly.

Related policy hubs

Independence Blue Cross policies Dermatology Oncology